Clinical Trial Update: Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

This clinical trial update reports the termination of a Phase 2 study of ibrutinib in adults with relapsed or refractory B-cell acute lymphoblastic leukemia, wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• Or Refractory B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 | Phase 2 | Status: TERMINATED | Results posted: 2017-01-16